フィルター
6 件の結果が “958” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
B6-hCD40
製品ID :
C001721
系統:
C57BL/6NCya
状況:
説明:
The CD40 gene encodes CD40, a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. Primarily expressed on antigen-presenting cells (APCs) such as B lymphocytes, macrophages, and dendritic cells, CD40 is also found on a variety of non-immune cells including endothelial cells, fibroblasts, epithelial cells, and smooth muscle cells, as well as many tumor cells [1]. The interaction of CD40 with its ligand, CD40L (CD154), expressed predominantly on activated T helper cells, is a critical costimulatory signal essential for T-dependent humoral and cell-mediated immunity. This interaction triggers downstream signaling pathways, including NF-κB, JNK, and JAK/STAT, leading to B cell activation, proliferation, differentiation, isotype switching, memory B cell development, germinal center formation, and enhanced APC function and cytokine production [2]. Dysregulation of CD40 signaling is implicated in the pathogenesis of numerous diseases, including autoimmune disorders like inflammatory bowel disease, type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, as well as cardiovascular diseases such as atherosclerosis, certain neurological conditions including Alzheimer's disease and traumatic brain injury, and various cancers [2-4]. Conversely, mutations in CD40 can lead to primary immunodeficiencies like autosomal recessive Hyper IgM syndrome [1]. Due to its central role in immune and inflammatory responses, CD40 is a significant target for therapeutic intervention, particularly in cancer immunotherapy and autoimmune diseases.
The B6-hCD40 mouse is a humanized model constructed by replacing the endogenous extracellular domain of the mouse Cd40 with the corresponding extracellular domain from the human CD40 gene. The murine signal peptide and transmembrane-cytoplasmic region were preserved. The B6-hCD40 mice can be used for studies on pathogenesis of cancer and autoimmune diseases, as well as for CD40-targeted drug development.
The CD40 gene encodes CD40, a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. Primarily expressed on antigen-presenting cells (APCs) such as B lymphocytes, macrophages, and dendritic cells, CD40 is also found on a variety of non-immune cells including endothelial cells, fibroblasts, epithelial cells, and smooth muscle cells, as well as many tumor cells [1]. The interaction of CD40 with its ligand, CD40L (CD154), expressed predominantly on activated T helper cells, is a critical costimulatory signal essential for T-dependent humoral and cell-mediated immunity. This interaction triggers downstream signaling pathways, including NF-κB, JNK, and JAK/STAT, leading to B cell activation, proliferation, differentiation, isotype switching, memory B cell development, germinal center formation, and enhanced APC function and cytokine production [2]. Dysregulation of CD40 signaling is implicated in the pathogenesis of numerous diseases, including autoimmune disorders like inflammatory bowel disease, type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, as well as cardiovascular diseases such as atherosclerosis, certain neurological conditions including Alzheimer's disease and traumatic brain injury, and various cancers [2-4]. Conversely, mutations in CD40 can lead to primary immunodeficiencies like autosomal recessive Hyper IgM syndrome [1]. Due to its central role in immune and inflammatory responses, CD40 is a significant target for therapeutic intervention, particularly in cancer immunotherapy and autoimmune diseases.
The B6-hCD40 mouse is a humanized model constructed by replacing the endogenous extracellular domain of the mouse Cd40 with the corresponding extracellular domain from the human CD40 gene. The murine signal peptide and transmembrane-cytoplasmic region were preserved. The B6-hCD40 mice can be used for studies on pathogenesis of cancer and autoimmune diseases, as well as for CD40-targeted drug development.
B6-hCD40/hCD40LG
製品ID :
C001781
系統:
C57BL/6NCya
状況:
説明:
The CD40 gene encodes CD40, a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. Primarily expressed on antigen-presenting cells (APCs) such as B lymphocytes, macrophages, and dendritic cells, CD40 is also found on a variety of non-immune cells including endothelial cells, fibroblasts, epithelial cells, and smooth muscle cells, as well as many tumor cells [1]. The CD40LG gene is located on the X chromosome (Xq26.3) and encodes CD40 ligand (CD40L, also known as CD154), a type II transmembrane protein mainly expressed on activated T cells, platelets, and some B cells. Under inflammatory conditions, monocytes, natural killer cells, mast cells, and basophils can also be induced to express CD40L [2-4].
The interaction of CD40 with its ligand, CD40L (CD154), is a critical costimulatory signal essential for T-dependent humoral and cell-mediated immunity. This interaction triggers downstream signaling pathways, including NF-κB, JNK, and JAK/STAT, leading to B cell activation, proliferation, differentiation, isotype switching, memory B cell development, germinal center formation, and enhanced APC function and cytokine production [5]. Dysregulation of CD40/CD40L signaling pathway is implicated in the pathogenesis of numerous diseases, including autoimmune disorders like inflammatory bowel disease (IBD), type 1 diabetes (T1D), multiple sclerosis, and rheumatoid arthritis (RA), as well as cardiovascular diseases such as atherosclerosis, certain neurological conditions including Alzheimer's disease (AD) and traumatic brain injury, and various cancers [5-7].
Due to the important role of the CD40/CD40L interaction in immune activation, CD40/CD40L has been an important target for immunotherapy. In recent years, significant progress has been made in CD40/CD40L-targeted therapy. Various drugs have been developed, including agonistic/antagonistic monoclonal antibodies, cellular vaccines, adenoviral vectors, and protein antagonists, and have shown therapeutic potential in malignant tumors, autoimmune diseases, and allograft rejection [1].
The B6-hCD40/hCD40LG mouse is a dual-gene humanized model (for CD40 and CD40LG) generated by crossing B6-hCD40 mice (Catalog No.: C001721) with B6-hCD40LG mice (Catalog No.: C001720). The B6-hCD40/hCD40LG mouse model can be used for research on the mechanisms and therapeutic approaches of diseases such as autoimmune diseases, cancer, and cardiovascular diseases, as well as for the development of CD40/CD40L-targeted drugs.
The CD40 gene encodes CD40, a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. Primarily expressed on antigen-presenting cells (APCs) such as B lymphocytes, macrophages, and dendritic cells, CD40 is also found on a variety of non-immune cells including endothelial cells, fibroblasts, epithelial cells, and smooth muscle cells, as well as many tumor cells [1]. The CD40LG gene is located on the X chromosome (Xq26.3) and encodes CD40 ligand (CD40L, also known as CD154), a type II transmembrane protein mainly expressed on activated T cells, platelets, and some B cells. Under inflammatory conditions, monocytes, natural killer cells, mast cells, and basophils can also be induced to express CD40L [2-4].
The interaction of CD40 with its ligand, CD40L (CD154), is a critical costimulatory signal essential for T-dependent humoral and cell-mediated immunity. This interaction triggers downstream signaling pathways, including NF-κB, JNK, and JAK/STAT, leading to B cell activation, proliferation, differentiation, isotype switching, memory B cell development, germinal center formation, and enhanced APC function and cytokine production [5]. Dysregulation of CD40/CD40L signaling pathway is implicated in the pathogenesis of numerous diseases, including autoimmune disorders like inflammatory bowel disease (IBD), type 1 diabetes (T1D), multiple sclerosis, and rheumatoid arthritis (RA), as well as cardiovascular diseases such as atherosclerosis, certain neurological conditions including Alzheimer's disease (AD) and traumatic brain injury, and various cancers [5-7].
Due to the important role of the CD40/CD40L interaction in immune activation, CD40/CD40L has been an important target for immunotherapy. In recent years, significant progress has been made in CD40/CD40L-targeted therapy. Various drugs have been developed, including agonistic/antagonistic monoclonal antibodies, cellular vaccines, adenoviral vectors, and protein antagonists, and have shown therapeutic potential in malignant tumors, autoimmune diseases, and allograft rejection [1].
The B6-hCD40/hCD40LG mouse is a dual-gene humanized model (for CD40 and CD40LG) generated by crossing B6-hCD40 mice (Catalog No.: C001721) with B6-hCD40LG mice (Catalog No.: C001720). The B6-hCD40/hCD40LG mouse model can be used for research on the mechanisms and therapeutic approaches of diseases such as autoimmune diseases, cancer, and cardiovascular diseases, as well as for the development of CD40/CD40L-targeted drugs.
Agtr1a-KO
製品ID :
S-KO-00958
系統:
C57BL/6NCya
状況:
説明:
Agtr1a is located on chromosome 13 of mice. Nuclease Technology was used to design sgRNA; Agtr1a knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Agtr1a is located on chromosome 13 of mice. Nuclease Technology was used to design sgRNA; Agtr1a knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Slc33a1-flox
製品ID :
S-CKO-00958
系統:
C57BL/6JCya
状況:
説明:
Slc33a1 is located on chromosome 3 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Slc33a1 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Slc33a1 is located on chromosome 3 of mice. SgRNA and ssDNA were designed using Nuclease Technology; Slc33a1 conditional knockout mice were obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp958-KO
製品ID :
S-KO-06681
系統:
C57BL/6JCya
状況:
説明:
Zfp958 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp958 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp958 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp958 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp958-flox
製品ID :
S-CKO-07704
系統:
C57BL/6JCya
状況:
説明:
Zfp958 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp958 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Zfp958 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp958 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Items: 1 to 6 of 6
1